Richard Norton peptides were at the center of a coroner’s finding that the 75-year-old died after taking double the prescribed dose and suffering a heart attack. The report filed Wednesday in the Coroners Court of Victoria says the injection, not the treatment itself as written on paper, was the fatal trigger.
David Ryan on the dose
David Ryan wrote that Norton had been taking amounts of the medication beyond what his medical practitioner prescribed. Two days before he died, Norton told his doctor’s nurse that he had been administering double the prescribed dose of CJC1295 and Ipamorelin, a detail that gives the finding its sharpest edge: the fatal sequence came after he moved past the instructions he had been given.
Jerzy Muchnicki and the prescription
On March 11, 2025, Norton saw Jerzy Muchnicki while recovering from shoulder surgery and said he was interested in peptide therapy. Muchnicki discussed the experimental nature of the treatment with him, and Norton signed a consent form before the peptides were prescribed. By March 25, Norton told Muchnicki that the therapy was improving his symptoms, which makes the later collapse harder to read as a simple failure of treatment alone.
On March 28, Norton told the nurse that he had dropped and broken a vial of CJC1295 and Ipamorelin and requested a replacement. The nurse spoke with Muchnicki by phone and he authorized the replacement. Later that evening, Judy Green reported that after Norton administered a second dose, he complained of feeling hot and flushed and then collapsed and became unresponsive.
Judy Green’s report
Green’s account is the most immediate human record in the file: Norton was rushed to a hospital, then died two days later on March 30, 2025. The Australian Broadcasting Corporation reported that the death appears to be the first fatality in Australia linked to unapproved peptides, which makes this case more than a private medical tragedy; it is now a reference point for how these therapies are discussed and monitored.
For readers weighing peptide treatment, the practical takeaway is plain. The record here turns on dose discipline, medical supervision, and the gap between a therapy described as experimental and a patient who later took more than was prescribed. The unanswered question is why Norton doubled the dose of CJC1295 and Ipamorelin, because the coroner’s file traces the final hours to that choice.
